# Trade Mark Journal No.2026/016 17 April 2026

## WO0000001846312 (5,40,42)

Office of origin: Japan

Date of International Registration:28 January 2025
Date of designation in the UK: 28 January 2025

Class 5
  Pharmaceutical preparations consisting of targeted protein degrader for the treatment of biliary tract cancer, pancreatic cancer, non-small cell lung cancer, prostate cancer, urothelial cancer, acute myeloid leukemia, glioblastoma, breast cancer, ovarian cancer, soft tissue sarcoma, diffuse large B cell lymphoma; pharmaceuticals consisting of targeted protein degrader for the treatment of biliary tract cancer, pancreatic cancer, non-small cell lung cancer, prostate cancer, urothelial cancer, acute myeloid leukemia, glioblastoma, breast cancer, ovarian cancer, soft tissue sarcoma, diffuse large B cell lymphoma; medicines for human purposes consisting of targeted protein degrader for the treatment of biliary tract cancer, pancreatic cancer, non-small cell lung cancer, prostate cancer, urothelial cancer, acute myeloid leukemia, glioblastoma, breast cancer, ovarian cancer, soft tissue sarcoma, diffuse large B cell lymphoma; targeted protein degrader for the treatment of biliary tract cancer, pancreatic cancer, non-small cell lung cancer, prostate cancer, urothelial cancer, acute myeloid leukemia, glioblastoma, breast cancer, ovarian cancer, soft tissue sarcoma, diffuse large B cell lymphoma.
Class 40
  Custom manufacture of pharmaceuticals consisting of targeted protein degrader for the treatment of biliary tract cancer, pancreatic cancer, non-small cell lung cancer, prostate cancer, urothelial cancer, acute myeloid leukemia, glioblastoma, breast cancer, ovarian cancer, soft tissue sarcoma, diffuse large B cell lymphoma.
Class 42
  Testing, inspection or research of pharmaceuticals consisting of targeted protein degrader for the treatment of biliary tract cancer, pancreatic cancer, non-small cell lung cancer, prostate cancer, urothelial cancer, acute myeloid leukemia, glioblastoma, breast cancer, ovarian cancer, soft tissue sarcoma, diffuse large B cell lymphoma; consulting services in the field of testing, inspection or research of pharmaceuticals consisting of targeted protein degrader for the treatment biliary tract cancer, pancreatic cancer, non-small cell lung cancer, prostate cancer, urothelial cancer, acute myeloid leukemia, glioblastoma, breast cancer, ovarian cancer, soft tissue sarcoma, diffuse large B cell lymphoma; providing medical and scientific testing, inspection or research information in the field of pharmaceuticals consisting of targeted protein degrader for the treatment of biliary tract cancer, pancreatic cancer, non-small cell lung cancer, prostate cancer, urothelial cancer, acute myeloid leukemia, glioblastoma, breast cancer, ovarian cancer, soft tissue sarcoma, diffuse large B cell lymphoma; conducting clinical trials for pharmaceuticals consisting of targeted protein degrader for the treatment of biliary tract cancer, pancreatic cancer, non-small cell lung cancer, prostate cancer, urothelial cancer, acute myeloid leukemia, glioblastoma, breast cancer, ovarian cancer, soft tissue sarcoma, diffuse large B cell lymphoma; research and development services in the field of pharmaceutical preparations consisting of targeted protein degrader for the treatment of biliary tract cancer, pancreatic cancer, non-small cell lung cancer, prostate cancer, urothelial cancer, acute myeloid leukemia, glioblastoma, breast cancer, ovarian cancer, soft tissue sarcoma, diffuse large B cell lymphoma.

Tanabe Pharma Corporation

Representative: Dehns, 10 Old Bailey LONDON EC4M 7NG UNITED KINGDOM